On December 6, 2017 Amgen (NASDAQ:AMGN) reported that it will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET (Press release, Amgen, DEC 6, 2017, View Source;p=RssLanding&cat=news&id=2321467 [SID1234522402]). David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen, together with other members of Amgen’s management team and a clinical investigator, will participate to discuss the Company’s oncology program, including our BiTE immunotherapy platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.